Bitopertin
- Generic Name
- Bitopertin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20F7N3O4S
- CAS Number
- 845614-11-1
- Unique Ingredient Identifier
- Q8L6AN59YY
- Background
Bitopertin has been used in trials studying the treatment of Schizophrenia and Obsessive-Compulsive Disorder.
- Associated Conditions
- -
- Associated Therapies
- -
How a patient helped shape a treatment for rare skin disorder
Dr Jasmin Barman-Aksӧzen, diagnosed with erythropoietic protoporphyria (EPP), joined a University of Zurich research group working on Scenesse, a treatment increasing skin pigmentation to protect against light-induced skin damage. Scenesse, approved in Europe in 2014 and the US in 2019, allows EPP patients to spend more time in sunlight without pain. Barman-Aksӧzen co-founded the International Porphyria Patient Network (IPPN) and advocates for head-to-head studies comparing new treatments to existing therapies.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath